Current treatment standards and future strategies in mantle cell lymphoma

被引：15

作者：

Dreyling, M. ^{[1
]}

Weigert, O. ^{[1
]}

Hiddemann, W. ^{[1
]}

机构：

[1] Univ Munich, Univ Hosp Grosshadern, Dept Internal Med 3, Munich, Germany

来源：

ANNALS OF ONCOLOGY | 2008年 / 19卷

关键词：

D O I：

10.1093/annonc/mdn193

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

[No abstract available]

引用

页码：41 / 44

页数：4

共 16 条

[1] Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network [J].

Dreyling, M ;

Lenz, G ;

Hoster, E ;

Van Hoof, A ;

Gisselbrecht, C ;

Schmits, R ;

Metzner, B ;

Truemper, L ;

Reiser, M ;

Steinhauer, H ;

Boiron, JM ;

Boogaerts, MA ;

Aldaoud, A ;

Silingardi, V ;

Kluin-Nelemans, HC ;

Hasford, J ;

Parwaresch, R ;

Unterhalt, M ;

Hiddemann, W .

BLOOD, 2005, 105 (07) :2677-2684

[2] Pathogenesis of mantle-cell lymphoma:: All oncogenic roads lead to dysregulation of cell cycle and DNA damage response pathways [J].

Fernàdez, V ;

Hartmann, E ;

Ott, G ;

Campo, E ;

Rosenwald, A .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (26) :6364-6369

[3] Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma [J].

Fisher, Richard I. ;

Bernstein, Steven H. ;

Kahl, Brad S. ;

Djulbegovic, Benjamin ;

Robertson, Michael J. ;

de Vos, Sven ;

Epner, Elliot ;

Krishnan, Amrita ;

Leonard, John P. ;

Lonial, Sagar ;

Stadtmauer, Edward A. ;

O'Connor, Owen A. ;

Shi, Hongliang ;

Boral, Anthony L. ;

Goy, Andre .

JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (30) :4867-4874

[4] A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma [J].

Hoster, Eva ;

Dreyling, Martin ;

Klapper, Wolfram ;

Gisselbrecht, Christian ;

van Hoof, Achiel ;

Kluin-Nelemans, Hanneke C. ;

Pfreundschuh, Michael ;

Reiser, Marcel ;

Metzner, Bernd ;

Einsele, Hermann ;

Peter, Norma ;

Jung, Wolfram ;

Woermann, Bernhard ;

Ludwig, Wolf-Dieter ;

Duehrsen, Ulrich ;

Eimermacher, Hartmut ;

Wandt, Hannes ;

Hasford, Joerg ;

Hiddemann, Wolfgang ;

Unterhalt, Michael .

BLOOD, 2008, 111 (02) :558-565

[5] Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: Molecular complete responses are not predictive of progression-free survival [J].

Howard, OM ;

Gribben, JG ;

Neuberg, DS ;

Grossbard, M ;

Poor, C ;

Janicek, MJ ;

Shipp, MA .

JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (05) :1288-1294

[6] Antitumor activity of rituximab plus thalidomide in patients with relapsed/refractory mantle cell lymphoma [J].

Kaufmann, H ;

Raderer, M ;

Wöhrer, S ;

Püspök, A ;

Bankier, A ;

Zielinski, C ;

Chott, A ;

Drach, J .

BLOOD, 2004, 104 (08) :2269-2271

[7] Sequential chemotherapy by CHOP and DHAP regimens followed by high-dose therapy with stem cell transplantation induces a high rate of complete response and improves event-free survival in mantle cell lymphoma:: a prospective study [J].

Lefrère, F ;

Delmer, A ;

Suzan, F ;

Levy, V ;

Belanger, C ;

Djabarri, M ;

Arnulf, B ;

Damaj, G ;

Maillard, N ;

Ribrag, V ;

Janvier, M ;

Sebban, C ;

Casasnovas, RO ;

Bouabdallah, R ;

Dreyfus, F ;

Verkarre, V ;

Delabesse, E ;

Valensi, F ;

McIntyre, E ;

Brousse, N ;

Varet, B ;

Hermine, O .

LEUKEMIA, 2002, 16 (04) :587-593

[8] Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma:: Results of a prospective randomized trial of the German low grade lymphoma study group (GLSG) [J].

Lenz, G ;

Dreyling, M ;

Hoster, E ;

Wörmann, B ;

Dührsen, U ;

Metzner, B ;

Eimermacher, H ;

Neubauer, A ;

Wandt, H ;

Steinhauer, H ;

Martin, S ;

Heidemann, E ;

Aldaoud, A ;

Parwaresch, R ;

Hasford, J ;

Unterhalt, M ;

Hiddemann, W .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (09) :1984-1992

[9] Quantitative assessment of molecular remission after high-dose therapy with autologous stem cell transplantation predicts long-term remission in mantle cell lymphoma [J].

Pott, C ;

Schrader, C ;

Gesk, S ;

Harder, L ;

Tiemann, M ;

Raff, T ;

Brüggemann, M ;

Ritgen, M ;

Gahn, B ;

Unlerhalt, M ;

Dreyling, M ;

Hiddemann, W ;

Siebert, R ;

Dreger, P ;

Kneba, M .

BLOOD, 2006, 107 (06) :2271-2278

[10] High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine [J].

Romaguera, JE ;

Fayad, L ;

Rodriguez, MA ;

Broglio, KR ;

Hagemeister, FB ;

Pro, B ;

McLaughlin, P ;

Younes, A ;

Samaniego, F ;

Goy, A ;

Sarris, AH ;

Dang, NH ;

Wang, M ;

Beasley, V ;

Medeiros, LJ ;

Katz, RL ;

Gagneja, H ;

Samuels, BI ;

Smith, TL ;

Cabanillas, FF .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (28) :7013-7023

← 1 2 →